Journal article · 2023 · Open access

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Stephen L Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Yongdong Jin, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng and 124 more

The Lancet, 402(10408), 1133–1146 · Published 24 July 2023 · DOI 10.1016/s0140-6736(23)00961-3

Open full textView at the publisherCite this paper

In brief

“Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study” is a 2023 journal article by Shukui Qin and 135 co-authors, published in The Lancet. OpenAlex counts 860 citations as of 21 November 2026. It is open access under a CC BY-NC-SA licence: the full text is free to read at Florence Research (University of Florence).

Citations
860
Most cited in
2025 (308)
Field-weighted impact
94.95
References
45
Authors
136

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jin, Y., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Cheng, Y., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., . . . Verset, G. (2023). Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet, 402(10408), 1133–1146. https://doi.org/10.1016/s0140-6736(23)00961-3

MLA 9

Qin, Shukui, et al. “Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.” The Lancet, vol. 402, no. 10408, 2023, pp. 1133–1146. https://doi.org/10.1016/s0140-6736(23)00961-3.

Chicago

Qin, Shukui, Stephen L Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, et al. 2023. “Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.” The Lancet 402 (10408): 1133–1146. https://doi.org/10.1016/s0140-6736(23)00961-3.

Harvard

Qin, S. et al. (2023) ‘Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study’, The Lancet, 402(10408), pp. 1133–1146. doi:10.1016/s0140-6736(23)00961-3.

IEEE

S. Qin et al., “Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study,” The Lancet, vol. 402, no. 10408, pp. 1133–1146, 2023, doi: 10.1016/s0140-6736(23)00961-3.

BibTeX

@article{qin2023camrelizumab,
  title     = {{Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study}},
  author    = {Qin, Shukui and Chan, Stephen L and Gu, Shanzhi and Bai, Yuxian and Ren, Zhenggang and Lin, Xiaoyan and Chen, Zhendong and Jin, Yongdong and Jin, Yongdong and Guo, Yabing and Hu, Xiaohua and Meng, Zhiqiang and Liang, Jun and Cheng, Ying and Xiong, Jianping and Ren, Hong and Yang, Fang and Li, Wei and Chen, Yajin and Zeng, Yong and Sultanbaev, Alexander and Pazgan-Simon, Monika and Pisetska, Margaryta and Melisi, Davide and Ponomarenko, Dmitriy and Osypchuk, Yurii and Sinielnikov, Ivan and Yang, Tsai-Sheng and Liang, Xiao and Chen, Chunxia and others},
  journal   = {The Lancet},
  year      = {2023},
  volume    = {402},
  number    = {10408},
  pages     = {1133--1146},
  doi       = {10.1016/s0140-6736(23)00961-3},
  url       = {https://doi.org/10.1016/s0140-6736(23)00961-3}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202211
20233232
2024256256
2025308308
2026262262

Its field-weighted citation impact is 94.95: it has been cited 94.95 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis

  • camrelizumab
  • apatinib
  • sorafenib
  • hepatocellular carcinoma
  • unresectable liver cancer
  • first-line therapy
  • immune checkpoint inhibitors
  • anti-PD-1 therapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jin, Y., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Cheng, Y., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., . . . Verset, G. (2023). Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet, 402(10408), 1133–1146. https://doi.org/10.1016/s0140-6736(23)00961-3

How many times has this paper been cited?

860 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Florence Research (University of Florence): sign in and open the full text from this page.

Who wrote this paper?

Shukui Qin, Stephen L Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Yongdong Jin, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng and 124 more.

What is the DOI of this paper?

10.1016/s0140-6736(23)00961-3, permanently at https://doi.org/10.1016/s0140-6736(23)00961-3. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.